Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL498184 | 0.69 | P2RX7 (0.46) | MEN1KMT2AP2RX7HSD11B1 | |
| SCHEMBL11535075 | 0.67 | MAPK14 (0.39) | ALDH1A1MEN1KMT2ATDP1MAPK14 | |
| SCHEMBL950144 | 0.66 | ATM (0.53) | ALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL28061546 | 0.65 | — | — | |
| SCHEMBL7510962 | 0.65 | — | — | |
| SCHEMBL20094462 | 0.64 | NR1H4 (0.40) | ALDH1A1MEN1KMT2ATDP1MAPK14 | |
| SCHEMBL28858824 | 0.63 | NOTUM (0.49) | ALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL950455 | 0.61 | ALDH1A1 (0.38) | ALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL11732101 | 0.61 | RAB9A (0.64) | ALDH1A1MEN1KMT2ANPSR1MAPK14 | |
| SCHEMBL8600146 | 0.61 | HCAR1 (0.37) | MAPK14NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106077-B2 | Compounds and methods for modulating FXR | ELI LILLY AND COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| EP-2029558-B1 | COMPOUNDS AND METHODS FOR MODULATING FXR | LILLY CO ELI (US) | 2010-03-10 | — | — | EP | disclosed |
| US-20090093524-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093524-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NR1H4, SLC10A1, FXR1 | ALDH1A1 2294/4885MEN1 4301/4885KMT2A 4324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.